Form 4: Pieris Pharmaceuticals Director Acquires Stock Options

A director of Pieris Pharmaceuticals, Christopher P. Kiritsy, acquired 500 stock options on December 2, 2024.

Summary

• Christopher P. Kiritsy, a director at Pieris Pharmaceuticals, acquired 500 stock options on December 2, 2024.
• The exercise price of these options is $16.43 per share.
• The options will vest 100% on December 2, 2025, contingent on Mr. Kiritsy's continued service as a director.
• The options expire on December 2, 2034.

Sentiment

Score: 6

Explanation: The document is neutral, detailing a routine stock option grant. It is neither particularly positive nor negative.

Positives

• The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for company directors and officers who have transactions involving company stock. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• Stock option grants to directors are a common practice across the biotechnology industry, used to align the interests of directors with those of shareholders.
• The vesting period of one year is fairly standard for such grants.
• The exercise price of $16.43 would be compared to the current market price of the stock to determine if the options are 'in the money'.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially encouraging actions that increase shareholder value.

Key Dates

Keywords

stock options, director, insider trading, equity, Pieris Pharmaceuticals, PIRS